• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lupin, MonoSol Rx ink licensing deal for pediatric products

October 11, 2016 By Sarah Faulkner

MonosolRx, LupinLupin Pharmaceutical (NSE:LUPIN) said last week that it inked a licensing agreement with MonoSol Rx to develop pediatric products using MonoSol’s drug-delivery technology.

Warren, N.J.-based MonoSol touts its dissolvable film, PharmaFilm, as a quick-dissolving system that’s easy to administer and masked by taste. The sublingual film is designed to support pediatric populations that often have trouble swallowing pills or tolerating more invasive delivery forms.

MonoSol has 2 FDA-approved products on the market using the PharmaFilm technology – Suboxone, for treating opioid dependence, and Zuplenz anti-nausea film.

Lupin hopes to expand into specialty pharmaceutical markets, particularly pediatric needs such as attention-deficit/hyper-activity disorder, according to the Baltimore, Md.-based company.

“We believe PharmFilm technology holds great promise for pediatric applications – enabling increased compliance and adherence in a difficult to treat population,” MonoSol Rx CEO Keith Kendall said in prepared remarks. “By partnering with Lupin, whose commitment to support and expand within the pediatric and family-focused market matches our own commitment to helping pediatric patients and their families, we are taking a critical step forward in developing valuable and much-needed products.”

“At Lupin, we are motivated by addressing urgent, unmet medical needs – and helping children and their families ensure they are able to access, tolerate and successfully take the medicines they need is a clear part of that mission,” added Lupin president Paul McGarty. “Our alliance with MonoSol Rx will enable us to expand our family of pediatric products to help meet the needs of children for a variety of indications.  We look forward to working with MonoSol Rx on the development of these products.”

Filed Under: Drug-Device Combinations, Featured, Pediatrics, Pharmaceuticals, Sublingual films Tagged With: Lupin Pharmaceutical, MonoSol Rx

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS